Background: This 8-week, randomized, double-blind, placebo-controlled study, conducted
August 2010–May 2012 in the United States, evaluated the safety and efficacy of …

ABSTRACT Context: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of
action thought to be related to a combination of 2 pharmacologic actions: direct modulation …

BackgroundVortioxetine has demonstrated dose-dependent efficacy in patients with major
depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg/day …

Aim This study assessed the efficacy and safety of vortioxetine in adults with major
depressive disorder. Methods In this double‐blind, placebo‐controlled study, 600 patients …

Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the
treatment of major depressive disorder (MDD). The current study evaluated the efficacy and …

Abstract Objective: Vortioxetine (Lu AA21004) is an investigational antidepressant. In vitro
studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5 …

Background Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing
of dose adjustment, in patients with major depressive disorder (MDD). Methods Pooled …

Objective: This article summarizes the US Food and Drug Administration's (FDA's) review of
the New Drug Application for vortioxetine, especially the clinical efficacy and safety data. It …

Vortioxetine is approved for the treatment of adults with major depressive disorder. This
open-label extension (OLE) study evaluated the safety and tolerability of vortioxetine in the …

Patients with major depressive disorder often experience relapse after responding to
treatment; therefore, maintenance therapy with antidepressants is recommended for …